Protein; For the first time, Bernese researchers have been able to solve the structure of a transport protein; and thus to describe the functional mechanism that plays a significant role in the survival of cancer cells. This is an important step towards developing effective inhibitors to fight tumor growth.

Certain cancer cells depend on exporting the metabolite lactate, which accumulates during the generation of energy. Lactate plays an important role in many biochemical and cellular processes. In healthy cells it is produced if our body is not supplying with enough oxygen during intensive exercise.

During this anaerobic energy production, lactate accumulates in cells and acidifies them. In certain cancer cells, metabolic processes are disturbing and large amounts of lactate are producing; even if the oxygen supply is sufficient to cover the energy demand. This phenomenon knowing as the “Warburg Effect,” which was observing for the first time Otto Warburg; for which discovery he was awarded the Nobel Prize for Physiology or Medicine in 1913.

Inhibiting transport pathways

Cancer cells use a transport protein, monocarboxylate transporter 4 (MCT4), to export lactate and thus to reduce cellular acidification. The transporter increases the lactate concentration outside the cell and acidifies the cell surrounding. This supports tumor growth and metastasis as the exported lactate is taken up into other cancer; cells by another transport protein (MCT1), where it serves as fuel.

Therefore, inhibiting MCT1 and MCT4 is a promising approach to fight certain types of cancer. However, so far no approved inhibitors for these transporters are on the market. “In order to develop such potent and highly selective inhibitors detailed knowledge of the structures of MCT1 and MCT4 is important”; says Dimitrios Fotiadis from the Institute of Biochemistry and Molecular Medicine (IBMM); but of the University of Bern and the National Centre of Competence in Research (NCCR) TransCure.

Both transporters belong to the so-called “Solute carrier 16” family (SLC16), which is responsible for the delivery of essential substances in the body and which also plays an important role in the uptake, action and excretion of drugs. Therefore, MCT1 and MCT4 are particularly suiting as therapeutic targets. No structure of an SLC16 lactate-transporter was determining and publishing until now. The research group of Dimitrios Fotiadis succeeded in this, and the results of the study have been recently published in the journal Nature Communications.

Discovery of promising protein

Fotiadis’ team published the first structure of a lactate-transporter of the SLC16-family (SfMCT); at high-resolution that is related to MCT1 and MCT4. “Based on this long sought-after structure of a protein of the SLC16-family we obtained insights into the molecular working mechanism of these proteins“; says Patrick Bosshart from the IBMM and the NCCR TransCure, who is first author of the study. The researchers also investigated the transport properties of SfMCT and possible binding sites for inhibitors.

“The solved structure of SfMCT together with our detailed transport study can contribute; to the structure-based design of drugs that target MCT1 and MCT4 using homology models,” says Dimitrios Fotiadis; who is last author of the study. The fact that the binding site in the solved structure of SfMCT; is accessible from the outside of the cell (so called “outward-open” conformation) is an important observation. This conformation is essential from a pharmacological perspective in order to generate models of MCT1 and MCT4 based; on the structure of SfMCT and to test inhibitors using these models.